Pharmaceuticals sales growth in China will continue to outstrip Europe and the US despite the economic slowdown on the mainland, downward pressure on drug prices and compliance challenges following the GlaxoSmithKline corruption scandal, according to the head of Swiss pharma group Novartis.
瑞士制藥集團諾華(Novartis)首席執行官江慕忠(Joe Jimenez)表示,中國醫藥銷售增速將繼續超過歐洲和美國,盡管中國經濟增速放緩、藥價面臨下調壓力,同時在葛蘭素史克(GSK)腐敗丑聞后面臨合規挑戰。
您已閱讀17%(397字),剩余83%(1961字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。